| Literature DB >> 30390665 |
Mimi Tang1,2, Ruili Dang3, Shao Liu1,2, Mengqi Zhang4, Yi Zheng5, Rui Yang1,2, Tao Yin6,7.
Abstract
BACKGROUND: The mechanisms underlying the association between immune activation and postpartum depression remained elusive. Although Ω-3 fatty acids possess anti-inflammatory properties, there is limited evidence directly linking the modulating effects of Ω-3 fatty acids on neuroimmune and neurochemistry to the antidepressant actions.Entities:
Keywords: NOD-like receptor pyrin domain containing 3 (NLRP3); Neuroinflammatary factors; Neurotransmission; Nuclear factor-kappaB (NF-kB); Purinergic type 2X7 (P2X7); Ω-3 fatty acids
Mesh:
Substances:
Year: 2018 PMID: 30390665 PMCID: PMC6215348 DOI: 10.1186/s12944-018-0894-2
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fatty acids composition of the Experimental Diets
| Fatty acids | Content in diet(area percent) | |
|---|---|---|
| Control | Supplementary | |
| C16:0 | 11.21 | 9.77 |
| C18:0 | 3.59 | 3.41 |
| C18:3n3 | 4.70 | 3.50 |
| C18:1n9c | 24.24 | 23.00 |
| C18:2n6c | 54.69 | 47.70 |
| C20:5n3 | ND | 6.96 |
| C22:6n3 | ND | 3.72 |
| Other MUFA | 1.56 | 1.95 |
Diet fatty acids composition was determined by GC/MS using Supelco 37 Standard. ND: Not detected
Fig. 1Performance in the behavior test. Immobility time in the FST (a); Sucrose preference in the SPT (b). #significantly different between reproductive status conditions (Two-way ANOVA followed by LSD post hoc test, n = 6–7 in each group)
Fig. 2Serum levels of proinflammatory factors. Effect of reproductive status and dietary conditions on serum IL-1a (a); Effect of reproductive status and dietary conditions on serum IL-1β (b); Effect of reproductive status and dietary conditions on serum IL-2 (c); Effect of reproductive status and dietary conditions on serum IL-6 (d); Effect of reproductive status and dietary conditions on serum IL-12 (e); Effect of reproductive status and dietary conditions on serum TNF-a (f); Effect of reproductive status and dietary conditions on serum IFN-γ (g). #significantly different between reproductive status conditions (Two-way ANOVA followed by LSD post hoc test, n = 6–7 in each group)
Fig. 3Protein levels in the prefrontal cortex. Protein expression of P2X7, NLRP3, NF-κB and β-actin in the prefrontal cortex (a); Effect of reproductive status and dietary conditions on protein levels of P2X7 in the prefrontal cortex (b); Effect of reproductive status and dietary conditions on protein levels of NLRP3 in the prefrontal cortex (c); Effect of reproductive status and dietary conditions on protein levels of NF-κB in the prefrontal cortex (d). #significantly different between reproductive status conditions and *significantly different between dietary conditions (Two-way ANOVA followed by LSD post hoc test, n = 6–7 in each group)
Fig. 4Protein levels in the hippocampus. Protein expression of P2X7, NLRP3, NF-κB and β-actin in the hippocampus (a); Effect of reproductive status and dietary conditions on protein levels of P2X7 in the hippocampus (b); Effect of reproductive status and dietary conditions on protein levels of NLRP3 in the hippocampus (c); Effect of reproductive status and dietary conditions on protein levels of NF-κB in the hippocampus (d). #significantly different between reproductive status conditions and *significantly different between dietary conditions (Two-way ANOVA followed by LSD post hoc test, n = 6–7 in each group)
The content of major neurotransmitters and their metabolites in the prefrontal cortex
| Compound | Virgin | Parous | ||
|---|---|---|---|---|
| Control | Supplementary | Control | Supplementary | |
| DA (ng/g) | 5.3 ± 0.6 | 5.4 ± 1.2 | 2.2 ± 0.3## | 3.4 ± 0.3# |
| DOPAC (ng/g) | 6.8 ± 0.9 | 10.1 ± 1.9 | 10.1 ± 1.0 | 7.7 ± 0.5 |
| HVA (ng/g) | 1.1 ± 0.2 | 1.3 ± 0.3 | 1.3 ± 0.1 | 1.8 ± 0.2 |
| NE (ng/g) | 8.2 ± 1.8 | 3.8 ± 0.9** | 3.3 ± 0.6## | 5.9 ± 0.7 |
| MHPG (ng/g) | 0.7 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 | 1.1 ± 0.1 |
| VMA(ng/g) | 1.2 ± 0.1 | 2.0 ± 0.4* | 0.6 ± 0.1 | 0.5 ± 0.1## |
| TRY (ug/g) | 9.2 ± 1.6 | 6.7 ± 1.4 | 8.2 ± 0.7 | 12.0 ± 1.0##,* |
| 5-HT (ng/g) | 153.7 ± 14.0 | 127.7 ± 31.3 | 116.0 ± 14.6 | 178.6 ± 26.1 |
| 5-HIAA (ng/g) | 373.9 ± 45.6 | 355.6 ± 27.0 | 304.0 ± 25.8 | 215.3 ± 11.02##,* |
| 5-HIAA/5-HT | 3.0 ± 0.4 | 3.2 ± 0.8 | 2.8 ± 0.4 | 1.2 ± 0.2#,* |
| KYN (ng/g) | 540.7 ± 99.0 | 429.0 ± 101.2 | 526.1 ± 51.4 | 622.2 ± 58.8 |
| GABA (ug/g) | 292.6 ± 41.5 | 200.3 ± 49.8 | 602.7 ± 82.8## | 730.1 ± 99.2## |
| GLU (ug/g) | 0.4 ± 0.06 | 0.3 ± 0.05 | 0.5 ± 0.06 | 0.7 ± 0.07 |
| GLN (ug/g) | 178.2 ± 25.2 | 132.0 ± 35.8 | 356.7 ± 41.5# | 501.0 ± 64.2## |
Data are means ± SEM (n = 6–7). #p < 0.05, ##p < 0.01 compared to virgin group; *p < 0.05, **p < 0.01compared to control group
The content of major neurotransmitters and their metabolites in the hippocampus
| Compound | Virgin | Parous | ||
|---|---|---|---|---|
| Control | Supplementary | Control | Supplementary | |
| DA (ng/g) | 6.3 ± 0.8 | 5.0 ± 0.7 | 4.2 ± 0.4# | 3.6 ± 0.5# |
| DOPAC (ng/g) | 3.1 ± 0.5 | 2.0 ± 0.2 | 3.1 ± 0.7 | 3.5 ± 0.7 |
| HVA (ng/g) | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.3 ± 0.0 | 0.4 ± 0.1 |
| NE (ng/g) | 3.8 ± 0.4 | 3.5 ± 0.5 | 2.7 ± 0.3 | 3.0 ± 0.3 |
| MHPG (ng/g) | 0.4 ± 0.0 | 0.3 ± 0.0 | 0.3 ± 0.0 | 0.3 ± 0.0 |
| VMA(ng/g) | 4.0 ± 0.3 | 3.5 ± 0.7 | 4.5 ± 0.4 | 3.5 ± 0.4 |
| TRY (ug/g) | 4.8 ± 0.3 | 4.0 ± 0.1 | 3.7 ± 0.1 | 4.6 ± 0.4 |
| 5-HT (ng/g) | 129.6 ± 17.9 | 105.5 ± 14.0 | 108.1 ± 9.1 | 121.1 ± 12.3 |
| 5-HIAA (ng/g) | 194.5 ± 30.3 | 166.8 ± 29.6 | 123.4 ± 9.5 | 71.8 ± 14.1## |
| 5-HIAA/5-HT | 1.8 ± 0.5 | 2.3 ± 0.6 | 0.7 ± 0.1 | 0.7 ± 0.2# |
| KYN (ng/g) | 282.6 ± 24.5 | 242.4 ± 6.9 | 222.8 ± 8.8 | 239.3 ± 14.4 |
| GABA (ug/g) | 63.3 ± 5.0 | 49.5 ± 3.1 | 31.6 ± 1.5## | 34.4 ± 1.5 |
| GLU (ug/g) | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 |
| GLN (ug/g) | 48.3 ± 3.7 | 38.0 ± 3.7 | 29.2 ± 1.3## | 32.5 ± 1.1 |
Data are means ± SEM (n = 6–7). #p < 0.05, ##p < 0.01 compared to virgin group; *p < 0.05, **p < 0.01compared to control group